for the unlabeled Ab and each of the Ab-F conjugates with absorption units (mAU) on the y-axis and retention time (minutes) on the x-axis. The RT of the major peak was used to assess the stability and purity of the Ab-F conjugates. All the Ab-Fs, except Ab-DyLight800 showed similar profiles for the major peak.
Supplementary Figure 3:
Comparison of blood concentration time-profile and PK parameters for unlabeled-Ab, Ab-AF680 and Ab-750. Ab concentrations were measured by LBA assay. PK parameters were similar between unlabeled-Ab, Ab-AF680
and Ab-750. 
Supplementary

BOD630
5 ± 1 6 ± 0.5 11 ± 6 3 ± 0.5 3 ± 0.4 2 ± 0.3 1 ± 0.3 0.1 ± 0.0 VT645 31 ± 3 3 ± 0.4 5 ± 1 10 ± 2 5 ± 1 16 ± 8 4 ± 1 2 ± 0.4 AF647 23 ± 3 3 ± 0.2 4 ± 1 8 ± 1 31 ± 0.5 9 ± 2 2 ± 0.4 2 ± 1 VT680 15 ± 3 22 ± 2 21 ± 2 7 ± 2 3 ± 1 3 ± 1 4 ± 2 2 ± 1 AF680 12 ± 2 1 ± 1 2 ± 2 3 ± 1 0.4 ± 0.2 1 ± 1 1 ± 1 0.1 ± 0.0 AF750 24 ± 5 0 0 12 ± 4 2 ± 1 10 ± 3 3 ± 1 1 ± 0.5 IRDye800 19 ± 5 7 ± 1 15 ± 4 30 ± 6 5 ± 1 11 ± 3 12 ± 5 5 ± 2 Ab concentration in organs at 96 h for each Ab-F, as calculated from ex vivo FMT data. The torso signal from FMT at 5 min and fresh organ weight were used as total dose for the calculation of % ID/g.
